Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 23.03M | 25.39M | 16.51M | 19.08M | 18.59M | 10.52M |
Gross Profit | 12.92M | 15.39M | 7.48M | 11.12M | 11.04M | 4.66M |
EBITDA | 4.51M | 6.21M | 1.96M | 3.73M | 5.66M | -2.91M |
Net Income | 1.92M | 3.52M | -39.48K | 1.79M | 1.63M | -6.23M |
Balance Sheet | ||||||
Total Assets | 39.30M | 38.10M | 35.65M | 33.15M | 28.83M | 15.60M |
Cash, Cash Equivalents and Short-Term Investments | 13.05M | 12.96M | 11.61M | 13.49M | 9.99M | 92.66K |
Total Debt | 6.44M | 6.40M | 6.65M | 5.82M | 7.74M | 6.17M |
Total Liabilities | 10.40M | 9.80M | 11.03M | 8.21M | 10.27M | 8.98M |
Stockholders Equity | 28.90M | 28.30M | 24.62M | 24.94M | 18.56M | 6.62M |
Cash Flow | ||||||
Free Cash Flow | 1.73M | 2.44M | -2.11M | 1.44M | 804.20K | -805.34K |
Operating Cash Flow | 3.80M | 4.35M | -1.09M | 3.47M | 2.11M | 8.57K |
Investing Cash Flow | -2.07M | -1.91M | -1.02M | -2.03M | -622.34K | -813.91K |
Financing Cash Flow | -1.46M | -1.08M | 229.21K | 2.06M | 8.41M | 802.43K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | C$65.80M | 17.34 | 14.51% | ― | 28.97% | ― | |
66 Neutral | C$41.47M | 25.43 | 5.32% | ― | -4.67% | -60.94% | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
50 Neutral | C$59.15M | ― | ― | -33.66% | -48.89% | ||
43 Neutral | $92.38M | ― | -211.24% | ― | ― | 0.10% | |
33 Underperform | C$50.92M | ― | 248.46% | ― | ― | 32.71% | |
33 Underperform | C$68.96M | ― | 685.26% | ― | ― | -50.29% |
Microbix Biosystems Inc. announced its participation in the Asia Pacific Conference on Point of Care Testing for Infectious Diseases in Bangkok, where it will present its quality assessment products (QAPs) that support point-of-care testing. The company will showcase its innovations that ensure diagnostic test accuracy, particularly for infectious diseases relevant to the Asia Pacific region. The presentation will highlight the robust performance of Microbix’s QAPs, which have been crucial in supporting SARS-CoV-2 tests and contributed to the company’s selection as a key quality control device partner in the EPICC initiative for HPV elimination. This engagement is expected to enhance Microbix’s role in point-of-care testing programs and expand its collaborations with diagnostics manufacturers.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems reported its Q2 fiscal 2025 results, showing a revenue of $5.3 million, a slight decrease from the previous year, but with improved gross margins. The company experienced growth in antigen sales, offset by a decline in QAPs due to delays with a major customer. Despite increased operating expenses, Microbix achieved a positive net income and improved financial strength, with strong cash reserves and liquidity. However, the outlook for the second half of fiscal 2025 is cautious due to reduced sales in China, impacting the company’s future growth prospects.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc., in collaboration with Aurevia Oy, has launched a pilot external quality assessment (EQA) program aimed at enhancing the proficiency of clinical laboratories in diagnosing bacterial vaginosis (BV) using molecular diagnostic methods. This initiative, which involves the use of Microbix’s QAPs to simulate clinical specimens, is expected to improve diagnostic accuracy and treatment planning for BV and other vaginal infections. The program’s success could lead to its inclusion in Aurevia’s Labquality EQAS portfolio, thereby strengthening Microbix’s position as a key partner in the diagnostics industry.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has announced the release of its second quarter fiscal 2025 financial results, scheduled for May 15, 2025. The company will host a webinar to discuss these results, featuring its CEO, CFO, and COO. This event reflects Microbix’s ongoing commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.
Microbix Biosystems Inc. announced that its partner, Sequel Pharma, has signed an agreement with a contract development and manufacturing organization (CDMO) to produce Kinlytic® urokinase, a drug for dissolving blood clots. This agreement aims to resume production for the U.S. market, initially targeting the catheter clearance segment valued at $400 million. The collaboration is expected to enhance Microbix’s market presence and operational capabilities, with future updates anticipated as the project progresses.
Microbix Biosystems Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, which will be held at the Metro Toronto Convention Centre. This event provides Microbix with a platform to connect with Canadian, U.S., and international investors, potentially enhancing its market presence and stakeholder engagement in the healthcare and life sciences sector.
Microbix Biosystems Inc. announced its participation in the ESCMID Global 2025 conference, where it will showcase its innovative Quality Assessment Products (QAPs) designed to ensure the accuracy of diagnostic tests. A customer and collaborator, Labquality EQAS by Aurevia, will present results from a pilot External Quality Assessment program for Norovirus antigen detection, supported by Microbix’s QAPs. This initiative highlights Microbix’s capability to create effective controls for challenging antigen materials, enhancing its industry positioning and demonstrating its commitment to quality management in diagnostics.
Microbix Biosystems Inc. announced that its products remain exempt from new U.S. tariffs, providing a competitive edge over other international exporters facing tariffs. The company is also exploring Canadian procurement opportunities amid potential reciprocal tariffs on U.S. goods. While the outlook for its QAPs business remains strong, sales of test-ingredients, particularly antigens, have been affected by reduced demand in China. Despite these challenges, Microbix continues to expand its capabilities and remains financially robust, with significant cash reserves and ongoing strategic initiatives in diagnostics and synthetic biology.